Roche Holding AG (RHHBY)
| Previous close | 38.25 |
| Open | 38.57 |
| Bid | 38.31 x 27000 |
| Ask | 38.34 x 40000 |
| Day's range | 38.17 - 38.67 |
| 52-week range | 29.20 - 42.43 |
| Volume | |
| Avg. volume | 1,718,517 |
| Market cap | 247.451B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 19.53 |
| EPS (TTM) | 1.96 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 1.35 (3.53%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 44.34 |
ZacksRoche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
ZacksRoche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.
GlobeNewswirePositive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritisGazyva/Gazyvaro is designed to target an underlying cause of lupus nephritis, aiming to prevent or delay progression to end-stage kidney disease1,2Lupus nephritis is a potentially life-threatening manifest
